caa a22 4500 475832965 CHVBK 20180406123845.0 cr unu---uuuuu 170329e20001201xx s 000 0 eng 10.1007/s100960000376 doi (NATIONALLICENCE)springer-10.1007/s100960000376 Population-Based Study on Incidence, Risk Factors, Clinical Complications and Drug Utilisation Associated with Influenza in the United Kingdom [Elektronische Daten] [C. R. Meier, P. N. Napalkov, Y. Wegmüller, T. Jefferson, H. Jick]  This large population-based study using the UK-based General Practice Research Database was conducted to quantify influenza-related physician visits, clinical complications of and risk factors for influenza, and related drug use in all age groups from 1991 to 1996. A total of 141,293 subjects who had one or more diagnoses of influenza or influenza-like illness during the study period as well as the same number of age-, sex-, practice and calendar time-matched controls were identified. Adults aged 15-64 years had the highest influenza incidence rate. The risk of getting influenza was particularly increased for subjects with chronic respiratory conditions (asthma or chronic obstructive pulmonary disease, odds ratio 1.65, 95% confidence interval 1.60-1.70). Subjects with influenza were more likely to have a diagnosis of clinical complications than control subjects (relative risk 3.4, 95% confidence interval 3.3-3.6). The risk of developing clinical complications was highest for children and was elevated for subjects with certain underlying chronic conditions. In absolute terms, otherwise healthy adults (15-64 years) accounted for the greatest proportion of all influenza-related physician visits as well as clinical complications in this study population. Of the 141,293 subjects with influenza, 83,911 (59.4%) received drugs on prescription. The most frequently prescribed drugs were antibiotics (45.2%), followed by antipyretics/analgesics (22.5%). Influenza patients were approximately six times more likely to use drugs on prescription than controls. This analysis may lead to further analyses on the economic impact of influenza and the contribution of different population groups to that burden. Springer-Verlag Berlin Heidelberg, 2000 Meier C. R. Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital, 4031 Basel, Switzerland e-mail: christoph.meier@unibas.ch, CH aut Napalkov P. N. Global Health Economics Group Pharmaceuticals Division, F Hoffmann-La Roche Ltd., 4070 Basel, Switzerland, CH aut Wegmüller Y. Global Health Economics Group Pharmaceuticals Division, F Hoffmann-La Roche Ltd., 4070 Basel, Switzerland, CH aut Jefferson T. Cochrane Vaccines Field, Camberley, Surrey, UK, GB aut Jick H. Boston Collaborative Drug Surveillance Program, Boston University Medical Center, 11 Muzzey Street, Lexington, MA 02421, USA, US aut https://doi.org/10.1007/s100960000376 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s100960000376 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Meier C. R. Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital, 4031 Basel, Switzerland e-mail: christoph.meier@unibas.ch, CH aut NATIONALLICENCE 700 1- Napalkov P. N. Global Health Economics Group Pharmaceuticals Division, F Hoffmann-La Roche Ltd., 4070 Basel, Switzerland, CH aut NATIONALLICENCE 700 1- Wegmüller Y. Global Health Economics Group Pharmaceuticals Division, F Hoffmann-La Roche Ltd., 4070 Basel, Switzerland, CH aut NATIONALLICENCE 700 1- Jefferson T. Cochrane Vaccines Field, Camberley, Surrey, UK, GB aut NATIONALLICENCE 700 1- Jick H. Boston Collaborative Drug Surveillance Program, Boston University Medical Center, 11 Muzzey Street, Lexington, MA 02421, USA, US aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer